Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified
Conditions
Interventions
None listed
Sponsors
Swansea University
Eligibility
Inclusion criteria
Inclusion criteria: Health Care Professional inclusion criteria â?? Phase 1b and 1d: a. Adults aged >=18 years b. Clinician, nurse, or other HCP (e.g., advanced practitioner) with specific senior expertise and experience ( >2 years) in the treatment and care of patients with PDAC (e.g., oncology, surgery, radiotherapy, specialist nurse, palliative care). c. Willingness to undertake an interview or written questionnaire in English. Patient participants inclusion criteria - Phase 1c and 1d a.Adults aged >=18 years b.Histologically proven as adenocarcinoma of the pancreas (head, body, tail) with disease stages I-IV. c.Are aware of their diagnosis and treatment plan. d.Patients receiving treatment (either currently or within the last 12 months) including a systemic treatment (chemotherapy, radiotherapy or chemoradiotherapy), biological and immunotherapy), surgical resection, and radiotherapy or receiving supportive or palliative care. e.Patients who are willing and able to give fully informed consent to participate. f.Patients who are currently enrolled in a clinical trial of a therapeutic agent (phase I-II) whose enrolment in this study is permitted under the trial eligibility criteria AND where any concurrent quality of life assessment (e.g., as part of the trial endpoint) will not affect the results of the current study.
Exclusion criteria
Exclusion criteria: Health Care Professional exclusion criteria - Phase 1b and 1d: a. HCPs under 18 years of age. b. HCPs with limited experience ( Patient participants exclusion criteria - Phase 1c and 1d: a. Patients under 18 years of age. b. Patients with concurrent malignancy. c. Patients enrolled in other quality of life studies which will affect the results of the current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome of this study will be to update the content and structure of the EORTC QoL Assessment System for patients with PDAC (EORTC QLQ-PAN26) for use in clinical trials and studies, which will subsequently provide the building blocks for a full international validation study. The research outputs will be a phase I-II report and provisional updated module (+/- item list) endorsed by the EORTC QLG and main outcome paper for submission reporting the phase I-II update of the EORTC HRQoL assessment module for patients with PDAC. Timepoint: On the day of enrolment. | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
Germany, India, Italy, Morocco, Norway, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States of America
Contacts
Public ContactDr Manjunath Nookala Krishnamurthy
Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre
Outcome results
None listed